Ipsen SA
Ipsen is a French biopharmaceutical company headquartered in Paris, France, with a focus on drug development and commercialization in three therapeutic areas: oncology, rare diseases and neuroscience. Ipsen is one of the world's top 15 biopharmaceutical companies in terms of oncology sales.
Filings
204 filings
- Ipsen - Bilan semestriel - 30 juin 2025Share buybackFrench
- Franchissement de seuilThreshold crossingFrench
- Ipsen S.A. - Initiation of the share buy-back programInside informationFR
- Ipsen S.A. - Annual General Meeting held on 21 May 2025Inside informationFR
- Ipsen publishes its 2024 Universal Registration DocumentUniversal registration documentFR
- Document d'enregistrement universel 2024Universal registration documentFrenchZIP
- Franchissements de seuilsThreshold crossingFrench
- franchissement de seuilThreshold crossingFrench
- Ipsen announces issuance of €500 million inaugural Rated Public BondInside informationFR
- Ipsen S.A. publishes its 2024 consolidated financial statementsInside information
- Ipsen S.A. publie ses comptes consolidés 2024Earnings releaseFrench
About
- ISIN
- FR0010259150
- Ticker
- IPN
- LEI
- 549300M6SGDPB4Z94P11
- Sector
- Health care
- Founded
- 1929
- Employees
- 5,300
- Country of registration
- FR
- Last filing
- 03/08/2026, 18:00
Description from Wikidata, CC0 licence.
Filing history
Filings per month
28
Sept 23May 24Jan 25Sept 25Aug 26
Document types
Across the whole archive